Veana Therapeutics LLC is categorized under Commercial Biotechnical Research in Portland, OR and active since 2013.
Veana Therapeutics LLC was established in 2013, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Emmanuel Akporiaye at the company’s single location by writing to 8417 Nw Adams St, Portland, Oregon OR 97229 or by phoning (503) 292-4065. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Veana Therapeutics LLC |
| Contact Person: | Emmanuel Akporiaye |
| Address: | 8417 Nw Adams St, Portland, Oregon 97229 |
| Phone Number: | (503) 292-4065 |
| Annual Revenue (USD): | $50.000 to $99.999 |
| Founded: | 2013 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Veana Therapeutics LLC was started in 2013 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.
Feel free to contact Emmanuel Akporiaye for inquiries that concern Veana Therapeutics LLC by calling the company number (503) 292-4065, as your correspondence is most welcome. Additionally, the physical location of the single location of Veana Therapeutics LLC can be found at the coordinates 45.532214,-122.764156 as well as the street address 8417 Nw Adams St in Portland, Oregon 97229.
For its online presence, you may visit Veana Therapeutics LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.